Handla om

Weekly or bi-weekly schedules, while offering improved injection comfort, often exhibit greater hormonal variability that requires careful dose titration to mitigate symptomatic oscillations. Daily injections tend to produce minimal hormone fluctuations, maintaining near steady-state testosterone concentrations that optimize receptor engagement and symptom control. Upon administration, testosterone disperses through the bloodstream and diffuses into target tissues where it binds to intracellular androgen hormone receptors.
Where things differ is in dosing preferences, primary goals, and how the results manifest. The libido improvements some users report are likely a combination of improved sleep, better IGF-1, and improved body composition — not a direct hormonal effect. As ipamorelin-driven fat loss reduces visceral fat, testosterone-to-estrogen ratio can improve passively. GH and IGF-1 play supporting roles in androgen metabolism and body composition. That said, the indirect effects are real and worth understanding.
Body changes come later — give it at least 3 months before evaluating whether it's working for body recomposition. People who quit after 4–6 weeks because "nothing happened" are the ones who miss the point of this peptide entirely. Some users also report a subtle but real improvement in general vitality — likely a combination of IGF-1 effects and improved sleep architecture.
Interestingly, previous data that used imaging (computed tomography or ultrasound) to estimate SC fat thickness and compared it with the length of the needle (or placement of the injectate) estimated that 12% to 85% of IM injections administered to men were actually SC (31-33). Owing to the convenience of self-administration of testosterone esters, the SC route has recently gained popularity. Selection of the administration route of testosterone is influenced by patient preference, product availability, and the cost of the formulation. More recently, newer formulations of testosterone replacement have become available, which include ultralong-acting testosterone undecanoate for IM injection, transdermal patches and gels, buccal tablets, intranasal sprays, and oral testosterone undecanoate (Table 1), thus providing a range of options to choose from. Currently, testosterone therapy is indicated for men with unequivocal, organic, or pathologic androgen deficiency to alleviate symptoms and maintain secondary sexual characteristics by raising testosterone into the normal male range (1). With appropriate training, patients should be able to safely self-administer testosterone esters SC with relative ease and less discomfort compared with the IM route. Systematic review of available literature on SC testosterone administration including clinical trials, case series, and case reports.
Mean A, 5-dihydrotestosterone (DHT) and B, estradiol (E2) concentrations on weekly subcutaneous (SC) injections of 75 mg testosterone enanthate. In summary, the stable and consistent serum testosterone concentrations after SC route of administration of testosterone enanthate and cypionate suggest that the SC route is a feasible option and can be self-administered by patients after appropriate training. In a prospective study, the effect of switching the route of testosterone therapy (with testosterone enanthate or cypionate) from the IM to the SC route was evaluated in 14 transgender men who had been on gender-affirming hormone therapy for at least 8 weeks (24). During week 7 of the study, the dose of testosterone was either reduced to 50 mg/week or increased to 100 mg/week with the aim of maintaining on-treatment serum testosterone levels within the normal range (27). In this study, testosterone enanthate was administered via IM (single 200-mg dose) or SC injection (50 or 100 mg/week for 6 weeks) to 39 hypogonadal men (serum total testosterone 25). As different muscle groups have variable blood flow (eg, the blood flow to the deltoids is higher than the glutei) (44), which further varies with physical activity (45), serum on-treatment testosterone concentrations after IM injections are dependent on these characteristics. Available evidence, though limited, suggests that SC testosterone therapy in doses similar to those given via IM route results in comparable pharmacokinetics and mean serum testosterone levels.

Kön: Kvinna